Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals

A technology of mammals and compositions, applied in the direction of drug combinations, pharmaceutical formulations, organic active ingredients, etc., can solve the problems of increasing arrhythmia and losing effect

Inactive Publication Date: 2013-06-12
LAGUNA PHARMA INC
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Another significant limitation or limitation of currently available class III antiarrhythmic agents is that their effects are potentiated or more pronounced during or during bradycardia or slow heart rates, and this would increase their arrhythmogenic potential
On the other hand, during tachycardia or conditions when these agents or drugs are expected and most needed, they almost lose their effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
  • Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.

[0025] As used herein, the term "pharmaceutically acceptable" relates to those compounds, materials, compositions, and / or dosage forms, which are suitable, within the scope of sound medical judgment, for contact with human and animal tissues and / or for use in for human and animal consumption without undue toxicity, irritation, allergic reaction, or other problematic complications commensurate with a reasonable benefit / risk ratio.

[0026] As used herein, "therapeutically effective amount" refers to an amount effective to reduce, eliminate, treat, prevent or manage the symptoms of the diseases and disorders described herein. The term "control" is intended to refer to all processes by which it is possible to slow, interrupt, arrest or stop the progression of the diseases and disorders described herein, but does not necessarily imply complete e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed are pharmaceutical compositions for and methods of preventing or treating acute and / or chronic cardiac arrhythmias in a mammal, including terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and / or maintaining normal sinus rhythm, which contain a combination of 1-[2-[(4- fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-[bis(4-fluorophenyl)- methoxy]ethyl]-4-(3-phenylpropyl)piperazine.

Description

technical field [0001] The present invention relates to pharmaceutical compositions for terminating acute episodes of arrhythmias, such as atrial fibrillation or ventricular fibrillation, in mammals such as humans, in particular comprising 1-[2-[(4-fluorophenyl)methoxy]ethyl A pharmaceutical composition of base]-4-(3-phenylpropyl)piperazine and a pharmaceutically acceptable carrier. The present invention also relates to a pharmaceutical composition for maintaining sinus rhythm in a mammal, such as a human, and thus preventing recurrence of arrhythmic episodes in such a mammal, in particular comprising 1-[2-[(4-fluorophenyl ) A pharmaceutical composition of methoxy]ethyl]-4-(3-phenylpropyl)piperazine and a pharmaceutically acceptable carrier. Background technique [0002] Atrial flutter and / or atrial fibrillation (AF) are the most common sustained cardiac arrhythmias in clinical practice, and their incidence is likely to increase with an aging population. Currently, AF affe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/497
CPCA61K31/495A61P9/06A61K2300/00
Inventor 阿瑟·M·布朗
Owner LAGUNA PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap